We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Subscribe To Our Newsletter & Stay Updated
